Vaginal candidiasis (commonly known as vaginal thrush) affects 138 million women worldwide each year.
Researchers have studied four Candida species (which account for 90% of candidiasis cases), the pathways they use to infect the vaginal epithelium and the defence mechanisms of this epithelium.
The results of this international collaboration between the group headed by Dr. Toni Gabaldon (IRB Barcelona / BSC) and Dr. Bernhard Hube’s laboratory (Hans Knoell Institute / University of Jena) have been published in the journal Nature Microbiology.
Candidiasis is a fungal infection caused by a yeast called Candida. It is a serious global health problem and it can be vaginal, oral or systemic. The latter is the most severe form of infection, as it can lead to death, but vaginal candidiasis infection is the most prevalent, affecting 80% of women at some point in their lives.
Scientists led by Dr. Toni Gabaldón, ICREA researcher and group leader at the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center (BSC), in collaboration with Dr. Bernhard Hube's group at the Hans Knoell Institute and the University of Jena in Germany, have described the various mechanisms used by the fungus Candida to infect the epithelium of the vagina and how human cells respond.
Candidiasis is caused by several species of fungus and the study has focused on the four species that cause 90% of cases: Candida albicans, C. glabrata, C. parapsylasis, and C. tropicalis. The researchers have observed that each species has a distinct infection pattern. However, vaginal epithelial cells respond in the same way to different species and the response is modulated according to the severity of the infection as it progresses.
"Understanding the infection processes and the interaction of the fungus with epithelial cells could contribute to the search for a treatment that anticipates the defence response, making it more effective," explains Dr. Gabaldón, head of the Comparative Genomics laboratory at IRB Barcelona and BSC.
A computational study of genetic patterns of infection and defence
Dr. Gabaldón's group has focused on the computational analysis of gene expression patterns of the different Candida species during infection. In this regard, they have quantified, analysed, and compared the genes that are activated and those that remain silent in both human and fungal cells, when infection by the different species of Candida begins.
"Knowing the genetic pattern that corresponds to the pathological process would allow work on a kit to detect infection," explains Hrant Hovhannisyan, co-first author of the study and PhD student of the Comparative Genomics laboratory.
Cell defence based on mitochondrial DNA
Analysis of the genetic defence response of human vaginal epithelial cells revealed that that it was based mainly on the action of mitochondria, the energy organelle of the cell. The researchers found that the mitochondria and even the cells release their DNA, thereby sending a signal to the immune system cells responsible for neutralising the infection.
"This system had previously been observed as a defence against viral infections and also some bacteria, but it is the first time it has been detected in response to a fungal infection," explains Dr. Gabaldón.
This work was carried out within the framework of an Innovative Training Networks (ITN) project funded within the Marie Skłodowska-Curie Actions call of the European Commission involving ten research groups from several European countries. "The excellence of the partners and the good environment for collaboration fostered by this type of project have allowed us to develop research with high added-value," says Dr. Gabaldón, who is also the project coordinator.
Marina Pekmezovic, Hrant Hovhannisyan, Mark S. Gresnigt, Elise Iracane, João Oliveira-Pacheco, Sofía Siscar-Lewin, Eric Seemann, Britta Qualmann, Till Kalkreuter, Sylvia Müller, Thomas Kamradt, Selene Mogavero, Sascha Brunke, Geraldine Butler, Toni Gabaldón & Bernhard Hube.
Candida pathogens induce protective mitochondria-associated type I interferon signalling and a damage-driven response in vaginal epithelial cells.
Nature Microbiology (2021) DOI: 10.1038/s41564-021-00875-2
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).